Immunization with a recombinant envelope protein (rgp90) of EIAV produces a spectrum of vaccine efficacy ranging from lack of clinical disease to severe enhancement.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Virology

• Publication date

  1998-05-25

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1006/VIRO.1998.9142PMID 9614876
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human HIV Vaccine Trials: Does Antibody-Dependent Enhancement Pose a Genuine Risk?

  2015cited by this paper
• Production of equine infectious anemia antigen in a persistently infected cell line

  2005cited by this paper
• Antibody-mediated enhancement of disease in feline infectious peritonitis: Comparisons with dengue hemorrhagic fever

  2002cited by this paper
• Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process

  1997cited by this paper
• Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope

  1997cited by this paper
• Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen.

  1996cited by this paper
• Replication in vitro and in vivo of an equine infectious anemia virus mutant deficient in dUTPase activity

  1995cited by this paper
• Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines

  1995cited by this paper
• Vaccines against Retroviruses

  1995cited by this paper
• Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.

  1994cited by this paper
• Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system

  1994cited by this paper
• Subtype cross-reactive, infection-enhancing antibody responses to influenza A viruses

  1994cited by this paper
• A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity

  1994cited by this paper
• Studies of High Doses of a Human Immunodeficiency Virus Type 1 Recombinant Glycoprotein 160 Candidate Vaccine in HIV Type 1-Seronegative Humans

  1994cited by this paper
• Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein.

  1994cited by this paper
• Reduced Virus Load in Rhesus Macaques Immunized with Recombinant gp160 and Challenged with Simian Immunodeficiency Virus

  1994cited by this paper
• Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials.

  1993cited by this paper
• Vaccines and adjuvants

  1992cited by this paper
• Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus

  1992cited by this paper
• Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages

  1992cited by this paper
• The Safety and Immunogenicity of a Human Immunodeficiency Virus Type 1 (HIV-1) Recombinant gp160 Candidate Vaccine in Humans

  1991cited by this paper
• The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network.

  1991cited by this paper
• Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals

  1990cited by this paper
• Complement-mediated, infection-enhancing antibodies in plasma from vaccinated macaques before and after inoculation with live simian immunodeficiency virus

  1990cited by this paper
• Equine infectious anemia virus (EIAV) Humoral responses of recipient ponies and antigenic variation during persistent infection

  1990cited by this paper
• Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization

  1990cited by this paper
• Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques

  1990cited by this paper
• Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever.

  1989cited by this paper
• Do antibodies enhance the infection of cells by HIV?

  1989cited by this paper
• Modulation of lentivirus replication by antibodies: Fc portion of immunoglobulin molecule is essential for enhancement of binding, internalization, and neutralization of visna virus in macrophages

  1989cited by this paper
• Antibody-dependent enhancement of human immunodeficiency virus type 1 infection.

  1988cited by this paper
• ANTIBODY-DEPENDENT ENHANCEMENT OF HIV INFECTION

  1988cited by this paper
• Antibody-dependent enhancement of HIV infection.

  1988cited by this paper
• Will antibody-dependent enhancement of HIV-1 infection be a problem with AIDS vaccines?

  1988cited by this paper
• Antibody-dependent enhancement of viral infectivity.

  1986cited by this paper
• Immune enhancement of viral infection.

  1982cited by this paper
• Protocol for the immunodiffusion (Coggins) test for equine infectious anemia

  1979cited by this paper

• Enhancement of viral infection by antibodies and consequences

  2025cites this paper
• Envelope Determinants of Equine Lentiviral Vaccine Protection

  2013cites this paper
• Lessons in AIDS Vaccine Development Learned from Studies of Equine Infectious, Anemia Virus Infection and Immunity

  2013cites this paper
• Equine infectious anemia and equine infectious anemia virus in 2013: a review.

  2013cites this paper
• A Pilot Study Comparing the Development of EIAV Env-Specific Antibodies Induced by DNA/Recombinant Vaccinia-Vectored Vaccines and an Attenuated Chinese EIAV Vaccine

  2012cites this paper
• Important mammalian veterinary viral immunodiseases and their control

  2012cites this paper
• Immunisation of pigs with a major envelope protein sub-unit vaccine against porcine reproductive and respiratory syndrome virus (PRRSV) results in enhanced clinical disease following experimental challenge

  2010influential citation
• EIAV envelope diversity: shaping viral persistence and encumbering vaccine efficacy.

  2010cites this paper
• Divergence, not diversity of an attenuated equine lentivirus vaccine strain correlates with protection from disease.

  2010cites this paper
• Viral load and clinical disease enhancement associated with a lentivirus cytotoxic T lymphocyte vaccine regimen.

  2009cites this paper
• Vaccines Against Retrovirus: Models and Chalenges in Development of a Vaccine Against HIV

  2009cites this paper
• Vaccine-induced enhancement of viral infections

  2008cites this paper
• FIV vaccine development: a continuing challenge

  2008cites this paper
• Vaccination of sheep with Maedi-visna virus gag gene and protein, beneficial or harmful?

  2007cites this paper
• HIV-1 gp120 Mannoses Induce Immunosuppressive Responses from Dendritic Cells

  2007cites this paper
• Vaccination with a T-cell-priming Gag peptide of caprine arthritis encephalitis virus enhances virus replication transiently in vivo.

  2007cites this paper
• The development of recombinant vaccines against Jembrana disease

  2007cites this paper
• Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines.

  2007cites this paper
• Envelope determinants of EIAV vaccine protection and the effects of sequence variation on immune recognition

  2007influential citation
• Envelope-specific T-helper and cytotoxic T-lymphocyte responses associated with protective immunity to equine infectious anemia virus.

  2007cites this paper
• In vivo Models of HIV Disease and Control

  2006cites this paper
• FIV as a Model for HIV: An Overview

  2006cites this paper
• Equine Infectious Anemia Virus as a Model for Lentiviral Pathogenesis

  2006cites this paper
• Lymphocyte Proliferation Responses Induced to Broadly Reactive Th Peptides Did Not Protect against Equine Infectious Anemia Virus Challenge

  2005influential citation
• EIAV (equine infectious anemia virus) : mieux comprendre la pathogenèse des infections lentivirales

  2005cites this paper
• Discerning an Effective Balance between Equine Infectious Anemia Virus Attenuation and Vaccine Efficacy

  2005cites this paper
• Evaluation of high functional avidity CTL to Gag epitope clusters in EIAV carrier horses.

  2005cites this paper
• Antibodies and PMBC from EIAV infected carrier horses recognize gp45 and p26 synthetic peptides.

  2005cites this paper
• Combined immunity of DNA vector and recombinant vaccinia virus expressing Gag proteins of equine infectious anemia virus

  2004cites this paper
• Equine Infectious Anemia Virus (EIAV): what has HIV's country cousin got to tell us?

  2004cites this paper
• CTL from EIAV carrier horses with diverse MHC class I alleles recognize epitope clusters in Gag matrix and capsid proteins.

  2004cites this paper
• Serological Method Using Recombinant S2 Protein To Differentiate Equine Infectious Anemia Virus (EIAV)-Infected and EIAV-Vaccinated Horses

  2004cites this paper
• Equine infectious anemia : 2001 update /

  2004cites this paper
• A Live Attenuated Equine Infectious Anemia Virus Proviral Vaccine with a Modified S2 Gene Provides Protection from Detectable Infection by Intravenous Virulent Virus Challenge of Experimentally Inoculated Horses

  2003influential citation
• Selecting peptides to optimize Th1 responses to an equine lentivirus using HLA-DR binding motifs and defined HIV-1 Th peptides

  2003cites this paper
• Production of Monospecific Antibody to Immunodominant Epitopes of the Caprine Arthritis Encephalitis Virus Transmembrane Glycoprotein and Analysis of Their Activity in vitro

  2002cites this paper
• Detection of horses infected naturally with equine infectious anemia virus by nested polymerase chain reaction.

  2001cites this paper
• Developments in preclinical AIDS vaccine efficacy models.

  2000cites this paper
• Antibody-dependent enhancement of HSV-1 infection by anti-gK sera.

  2000cites this paper
• Tissue Sites of Persistent Infection and Active Replication of Equine Infectious Anemia Virus during Acute Disease and Asymptomatic Infection in Experimentally Infected Equids

  2000cites this paper
• The S2 Gene of Equine Infectious Anemia Virus Is a Highly Conserved Determinant of Viral Replication and Virulence Properties in Experimentally Infected Ponies

  2000cites this paper
• Immune Responses and Viral Replication in Long-Term Inapparent Carrier Ponies Inoculated with Equine Infectious Anemia Virus

  2000cites this paper
• Evaluation of antibody parameters as potential correlates of protection or enhancement by experimental vaccines to equine infectious anemia virus.

  1999cites this paper
• In vitro antibody-dependent enhancement assays are insensitive indicators of in vivo vaccine enhancement of equine infectious anemia virus.

  1999cites this paper
• A particulate viral protein vaccine reduces viral load and delays progression to disease in immunized ponies challenged with equine infectious anemia virus.

  1999cites this paper
• Effects of long terminal repeat sequence variation on equine infectious anemia virus replication in vitro and in vivo.

  1999cites this paper